Merck (MRK +0.8%) shares rise on the company's FDA approval to launch a new hepatitis C drug...

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

Merck (MRK +0.8%) shares rise on the company's FDA approval to launch a new hepatitis C drug after evaluating the safety and effectiveness of the treatment in two phase-3 clinical trials. Rival Vertex (VRTX -0.4%) also awaits FDA approval of its new hepatitis C drug later this month, but one analyst believes Merck should capture 20-30% of the global market hepatitis C market.